Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden Abstract #2997

Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.
Aim(s): To report outcomes (including QoL) of two male patients aged 49 years with advanced, metastatic NETs treated with 177Lu-DOTATATE.
Materials and methods: Patient A had a midgut NET (grade 2; Ki-67: 5–10%) with liver, mesenteric node and likely bone metastases. He received treatment with a somatostatin analogue (SSA). Patient B had a pancreatic NET (grade 2; Ki-67: 18%). After resection, the NET recurred with extensive liver metastases and became insulin-secreting. The patient successively received an SSA, chemotherapy, everolimus and liver embolization. Continuous dextrose infusion was used to prevent hypoglycaemia. Both patients subsequently received PRRT with four cycles of 177Lu-DOTATATE.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Jonathan Wadsley
Authors: Wadsley J, Shah T

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2797 Assessment of Quality of Life in Patients with Neuroendocrine Tumours: Results of a Systematic Literature Review
Introduction: Health related quality of life (HRQoL) is increasingly important as a concept reflecting the patients’ perspective in conjunction with the disease presentation severity and treatment. Understanding the impact of treatment on neuroendocrine tumour (NET) patients’ HRQoL is paramount given the nature of the disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: Dr Persefoni Ioannou
#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile
Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Diego Carrillo
#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye
#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Ph.D. Arthur Braat
Authors: Braat A, Rutger B, Van Rooij R, Braat M, ...
#3037 Effects of Debulking Surgery, Transarterial Embolisation (TAE) and Transarterial Chemoembolisation (TACE) on Quality of Life in Patients with Metastatic Ileal and Pancreatic Neuroendocrine Tumours (NETs)
Introduction: Debulking surgery, TAE and TACE procedures are undertaken in patients with metastatic NETs. Reducing the physical burden of disease may prolong survival and can improve the quality of life of patients. However, there is only limited quality of life data available after surgery despite the fact that is has been used routinely for many years.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Adam Sinclair
Authors: Sinclair A, Tanno L, Jarvis E, Ramsey E, ...